FLT3 and myeloid leukemia: Despite lacking formal approval for myeloid leukemia, sorafenib’s off-label use in FLT3-ITD mutated acute myeloid leukemia (AML) and demonstrated clinical activity in FLT3-wildtype AML have contributed to 2.89% of total publications in this domain (Borthakur et al., 2011; Roskoski, 2020; Pratz et al., 2010).